本帖最后由 老马 于 2013-3-13 13:43 编辑 : L" ^ H+ X$ p0 \* R
! g* F0 C# c3 |2 l3 X) |
健择（吉西他滨）+顺铂+阿瓦斯汀% ~* u6 S0 {5 ~7 @. i# |
Gemzar +Cisplatin + Avastin
3 h+ I) b# A* p. a, B4 Yhttp://annonc.oxfordjournals.org/content/21/9/1804.full" E- G9 _% Q9 \* x4 i
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 9 R; z$ L- C* M' Z- r
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
) b6 s$ r w) ^2 L; k7 R; CResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. : M& H G8 }" k! s- c2 }( @
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1141)
/ }& f& V, M/ P5 R
华为网盘附件： A: U) M1 Y2 i7 P
【华为网盘】ava.JPG
% z$ ?' i) Q1 i) I: [3 @ |
11011102001537 )
显身卡
